Sign in Subscribe
Class action lawsuits

Alto Neuroscience Class Action Lawsuit Filed

Strategic Insights

— 1 min read

A securities class action lawsuit has been filed against Alto Neuroscience, Inc. (NYSE: ANRO) alleging that the company made materially false and misleading statements regarding its business, operations, and prospects. The lawsuit claims that investors suffered damages due to the Company's false and/or misleading statements about the effectiveness of its ALTO-100 treatment for major depressive disorder (MDD) and its clinical, regulatory, and commercial prospects.

Key Takeaways:

  • The lawsuit alleges that Alto Neuroscience made false and/or misleading statements about the effectiveness of its ALTO-100 treatment for MDD and its clinical, regulatory, and commercial prospects.
  • The offering documents and defendants made false and/or misleading statements and/or failed to disclose that ALTO-100 was less effective than they had led investors to believe.
  • The lawsuit claims that investors suffered damages due to the Company's false and/or misleading statements.
  • The Rosen Law Firm, a global investor rights law firm, is representing investors in this class action lawsuit.
  • Investors have until September 19, 2025, to serve as lead plaintiff in the case.
  • The Rosen Law Firm has a track record of success in securities class actions and shareholder derivative litigation, with over $438 million recovered for investors in 2019 alone.

Statistics:

  • The lawsuit covers common stock of Alto Neuroscience, Inc. (NYSE: ANRO) purchased pursuant and/or traceable to the Company's initial public offering on or about February 2, 2024, and/or securities between February 2, 2024, and October 22, 2024.
  • The Class Period is defined as the period between February 2, 2024, and October 22, 2024, both dates inclusive.
  • The lead plaintiff deadline is September 19, 2025.
  • Alto Neuroscience, Inc. has over 12 million shares of common stock outstanding.

Sources:

  • Newsfile Corp. - August 12, 2025
  • The Rosen Law Firm, P.A.
  • Securities and Exchange Commission (SEC) filings
  • Alto Neuroscience, Inc. (NYSE: ANRO) investor presentations

Read more